Truist lowered the firm’s price target on Teleflex (TFX) to $200 from $227 and keeps a Hold rating on the shares as part of a broader research note previewing 2025 in Medical Technology. The firm sees the sector as “one of the better/safer houses” in healthcare given its lower “front-line” exposure to healthcare policy rhetoric that is tied to the administration change as well as its position as an “innovation segment” with sustainable above-average revenue and EPS growth, strong balance sheets, and healthy free cash flows. Truist adds that it prefers small-mid size companies over large caps as M&A may be “poised to heat up”.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFX:
- Teleflex in talks to buy Biotronik stent unit, Bloomberg says
- Teleflex price target lowered to $227 from $255 at Truist
- Teleflex price target lowered to $245 from $266 at Raymond James
- Teleflex price target lowered to $250 from $275 at Mizuho
- Teleflex price target lowered to $245 from $275 at RBC Capital